Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
-
Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
-
WinVest Acquisition Corp. Announces Full Exercise of $15 Million Over-Allotment Option by Underwriters
-
WinVest Acquisition Corp. Announces Full Exercise of $15 Million Over-Allotment Option by Underwriters
-
Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
-
Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
-
Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
-
Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference
-
Passage Bio to Participate in Upcoming October Conferences
-
Passage Bio to Participate in Upcoming October Conferences
-
Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
-
Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
-
Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
-
Solid Biosciences (SLDB) PT Lowered to $17 at Chardan Capital Markets, Keeps 'Buy' Rating Amid SGT-001 Data
-
Form 10-Q Chardan NexTech Acquisit For: Jun 30
-
Sio Gene Therapies to Participate in Upcoming Conferences
-
Synlogic (SYBX) Prices 15M Share Stock Offering at $3/sh
-
Synlogic Announces Pricing of Public Offering of Common Stock
-
Pacifico Acquisition Corp. Announces Closing of Over-Allotment Option in Connection With Its Initial Public Offering
-
Pacifico Acquisition Corp. Announces Closing of Over-Allotment Option in Connection With Its Initial Public Offering
-
Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
-
Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
-
Solid Biosciences to Participate at Upcoming Investor Conferences
-
UPDATE: Chardan Capital Markets Upgrades Forte Biosciences Inc. (FBRX) to Neutral
-
WinVest Acquisition Corp. Announces Closing of $100 Million Initial Public Offering
-
WinVest Acquisition Corp. Announces Closing of $100 Million Initial Public Offering
-
DTx Pharma to Present at Upcoming Investor Conferences
-
IPO for SPAC WinVest Acquisition Corp. (WINV) Opens at $10.07
-
WinVest Acquisition Corp. (WINVU) Prices 10M Unit IPO at $10/unit
-
WinVest Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
-
WinVest Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
-
Pacifico Acquisition Corp. (PAFOU) Prices 5M Unit IPO at $10/unit
-
Pacifico Acquisition Corp. Announces Pricing of $50 Million Initial Public Offering
-
Pacifico Acquisition Corp. Announces Pricing of $50 Million Initial Public Offering
-
REGENXBIO to Participate in Upcoming Investor Conferences
-
Abri SPAC I, Inc. Announces the Separate Trading of its Common Stock and Warrants, Commencing September 8, 2021
-
Form 25-NSE Chardan Healthcare Acqui Filed by: NYSE AMERICAN LLC
-
Form 8-K Chardan Healthcare Acqui For: Sep 01
-
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange
-
Metagenomi Announces Participation in Fall Investor Conferences
-
Chardan Healthcare Acquisition 2 Corp (CHAQ) Stockholders Approve Merger with Renovacor, Inc
-
Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.
-
CHW Acquisition Corporation Announces Closing of Upsized $125,000,000 Initial Public Offering Including Partial Exercise of Over-Allotment Option
-
Avidity Biosciences to Participate in Upcoming Investor Conferences
-
Mesoblast Limited (MESO) PT Lowered to $6.50 at Chardan Capital Markets
-
Form DEFA14A Chardan Healthcare Acqui
-
IPO for SPAC CHW Acquisition Corporation (CHWA) Opens at $9.88
-
CHW Acquisition Corporation (CHWAU) Prices Upsized 11M Unit Offering at $10/unit
-
CHW Acquisition Corporation Announces Upsized Pricing of $110,000,000 Initial Public Offering
-
Form DEFA14A Chardan Healthcare Acqui

